The 18th Annual Molecular Med TRI-CON will bring together the therapeutic and diagnostic aspects of the molecular medicine industry to discuss cutting-edge research, trends and analysis. Areas of interest include molecular diagnostics, personalized diagnostics, cancer molecular markers, circulating tumor cells, translational science, stem cells, cancer biologics, pathway-targeted therapies in cancer, and medicinal chemistry.
Theresa LaVallee, Director of Research & Development, will speak on the topics of "What and How to Establish Effective Science Driven Drug Development" and "Translational Sciences in Oncology: A Risk Mitigation Strategy"
Dowdy Jackson, will speak on the topic of "Early Stage Antibody Drug Conjugate Development, preparations for the clinic"
Robert Hollingsworth, Director of Cancer Biology, will speak on the topic of "Identification, Characterization and Targeting of Cancer Stem Cells"
Brandon Higgs will speak on the topic of "Planning for a Biomarker Strategy in All Phases of Drug Development: Advantages of a Translational Approach"
Robert Lechleider, Director of Clinical Development, Oncology ,will speak on the topic of "Accelerated Approval in Oncology"
Daniel Ingber, Senior Manager of Research Information Systems, will speak on the topic of "Implementing a Biomarker Data Mining System"
Ross Stewart, will speak on the topic of "Delivering Effective Blockade of Immunosupression to Enhance Tumour Rejection: Monoclonal Antibody Discovery and Pre-Clinical Development"
Bryan Takasaki, Science Director, R&D Information, from AstraZeneca will speak on the topic of "Integrating Knowledge from the Bench, Literature and the Clinic: Successes and Challenges"
Added by MedImmune on January 20, 2011